FDA — authorised 29 November 2021
- Marketing authorisation holder: ON TARGET LABROTORIES, INC
- Status: approved
🇺🇸 Cytalux in United States
FDA authorised Cytalux on 29 November 2021
Marketing authorisations
FDA — authorised 29 November 2021
- Application: NDA214907
- Marketing authorisation holder: ON TARGET LABS
- Local brand name: CYTALUX
- Indication: SOLUTION — INTRAVENOUS
- Status: approved
Cytalux in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in United States
Frequently asked questions
Is Cytalux approved in United States?
Yes. FDA authorised it on 29 November 2021; FDA authorised it on 29 November 2021.
Who is the marketing authorisation holder for Cytalux in United States?
ON TARGET LABROTORIES, INC holds the US marketing authorisation.